Background
Methods
Variable assessment
Statistical approach
Cardiovascular event history or conditions
|
N
|
Ischemia/infarction | 2 |
Cardiac insufficiency | 4 |
Atrial fibrillation | 3 |
Ventricular arrhythmia/tachycardia | 5 |
Bradycardia | 3 |
Ventricular hypertrophy | 2 |
Angina | 6 |
Hypertension (diagnosed) | 185 |
(BP > 130/85 mmHg, or treatment of diagnosed) | 249 |
Ischemic heart disease | 6 |
Diseases of the pulmonary circulation | 3 |
Stroke | 4 |
Cerebrovascular diseases | 11 |
Diseases of arteries, arterioles or capillaries | 6 |
Cardiometabolic conditions
| |
Metabolic syndrome | 352 |
(excluding diagnosed type 2 diabetics/FG ≥ 7 mmol/L) | 140 |
Gestational diabetes (history of) | 23 |
Type 1 diabetes | 1 |
Type 2 diabetes (diagnosed) | 140 |
(diagnosed or FG ≥ 7 mmol/L) | 176 |
Cardiovascular drug/supplement use
| |
Antiplatelet | 6 |
Antihypertensives | 183 |
Diuretics (specifically) | 62 |
Cholesterol-lowering drugs | 79 |
Statins (specifically) | 73 |
Multivitamins | 41 |
Mg supplements | 8 |
Hormonal or menstrual status
| |
Post-menopausal | 104 |
Hormone replacement therapy | 1 |
Oral contraceptives | 92 |
Currently breastfeeding | 35 |
Other
| |
Kidney disease | 13 |
Cancer | 6 |
Results
Characteristic | No PVC n = 591 | 1-6 PVC/hr n = 118 | > 6 PVC/hr n = 41 |
---|---|---|---|
Sex | |||
Male
| 217 (37%) | 64 (54%) | 28 (68%) |
Female
| 374 (63%) | 54 (46%) | 13 (32%)*** |
Age (yrs) | |||
18-30
| 194 (33%) | 23 (19%) | 5 (12%) |
30-50
| 302 (51%) | 44 (37%) | 14 (34%) |
≥ 50
| 95 (16%) | 51 (43%) | 22 (54%)*** |
BMI (kg/m2) | |||
< 30
| 170 (29%) | 36 (31%) | 8 (20%) |
≥ 30
| 421 (71%) | 82 (69%) | 33 (80%) |
Smoking | |||
Current
| 329 (56%) | 40 (34%) | 16 (39%) |
Former
| 204 (34%) | 61 (52%) | 21 (51%) |
Never
| 58 (10%) | 17 (14%) | 4 (10%)*** |
Alcohol1 | |||
< 3 drinks/d
| 271 (46%) | 48 (41%) | 10 (24%) |
Never
| 312 (54%) | 69 (59%) | 31 (76%)** |
Exercise | |||
≥ 4 times/wk
| 187 (32%) | 37 (31%) | 13 (32%) |
1-3 times/wk
| 217 (36%) | 32 (27%) | 10 (24%) |
None
| 187 (32%) | 49 (42%) | 18 (44%)** |
Hypertension | 153 (26%) | 41 (35%) | 15 (37%)* |
CVD history1 | 18 (3%) | 7 (6%) | 4 (10%)** |
MetS2 | 95 (16%) | 30 (25%) | 15 (37%)*** |
Diabetes3 | 122 (21%) | 37 (31%) | 17 (41%)*** |
sMg (mmol/L) | ≤ 0.7 | 0.71-0.80 | 0.81-0.90 | > 0.90 |
---|---|---|---|---|
Model 1 | 1.00 | 0.26 (0.07-0.88) | 0.27 (0.08-0.93) | 0.22 (0.06-0.81) |
Model 2 | 1.00 | 0.25 (0.07-0.85) | 0.26 (0.08-0.88) | 0.19 (0.05-0.71) |
Model 3 | 1.00 | 0.25 (0.07-0.85) | 0.26 (0.08-0.88) | 0.20 (0.05-0.73) |
Model 4 | 1.00 | 0.24 (0.07-0.86) | 0.25 (0.07-0.92) | 0.19 (0.05-0.77) |
Model 5 | 1.00 | 0.24 (0.07-0.87) | 0.26 (0.07-0.93) | 0.18 (0.04-0.73) |
Type 2 diabetics sMg ≤ 0.70 mmol/L | Type 2 diabetics sMg > 0.70 mmol/L | |
---|---|---|
Model 1 | 1.00 | 0.28 (0.08-0.98) |
Model 2 | 1.00 | 0.25 (0.07-0.92) |
Model 3 | 1.00 | 0.26 (0.07-1.04) |
Model 4 | 1.00 | 0.25 (0.06-1.03) |
Model 5 | 1.00 | 0.24 (0.06-0.98) |